NASDAQ:OMCL - Omnicell Stock Price, Price Target & More

Get Started

$45.85 +0.20 (+0.44 %)

(As of 05/27/2018 07:42 AM ET)

Previous Close$45.85

Today's Range$45.65 - $46.35

52-Week Range$39.75 - $55.40

Volume148,473 shs

Average Volume274,004 shs

Market Capitalization$1.78 billion

P/E Ratio254.72

Dividend YieldN/A

Beta0.76

About Omnicell (NASDAQ:OMCL)

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electronic computers

Sub-IndustryHealth Care Technology

SectorMedical

SymbolNASDAQ:OMCL

CUSIP68213N10

Webwww.omnicell.com

Phone650-251-6100

Debt

Debt-to-Equity Ratio0.33

Current Ratio1.68

Quick Ratio1.22

Price-To-Earnings

Trailing P/E Ratio254.72

Forward P/E Ratio33.22

P/E Growth2.11

Sales & Book Value

Annual Sales$716.16 million

Price / Sales2.49

Cash Flow$1.5898 per share

Price / Cash28.84

Book Value$14.78 per share

Price / Book3.10

Profitability

EPS (Most Recent Fiscal Year)$0.18

Net Income$20.60 million

Net Margins4.55%

Return on Equity4.11%

Return on Assets2.15%

Miscellaneous

Employees2,350

Outstanding Shares38,880,000

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, April, 26th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.04. The company had revenue of $182.60 million for the quarter, compared to the consensus estimate of $177.49 million. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 earnings per share. View Omnicell's Earnings History.

When is Omnicell's next earnings date?

Omnicell is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $1.85-$2.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.97. The company issued revenue guidance of $780-$800 million, compared to the consensus revenue estimate of $790.31 million.Omnicell also updated its Q2 guidance to $0.36-$0.42 EPS.

What price target have analysts set for OMCL?

6 brokerages have issued 12 month price targets for Omnicell's shares. Their predictions range from $44.00 to $67.00. On average, they anticipate Omnicell's stock price to reach $56.6667 in the next twelve months. View Analyst Ratings for Omnicell.

What are Wall Street analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)

Who are some of Omnicell's key competitors?

Some companies that are related to Omnicell include Nice (NICE), Capcom (CCOEY), Teradata (TDC), Fitbit (FIT), Super Micro Computer (SMCI), Cray (CRAY), Huami (HMI), One Stop Systems (OSS) and Socket Mobile (SCKT).

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:

Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)

Has Omnicell been receiving favorable news coverage?

News articles about OMCL stock have trended positive on Sunday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omnicell earned a daily sentiment score of 0.42 on Accern's scale. They also gave news headlines about the company an impact score of 46.47 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.56%), Dimensional Fund Advisors LP (3.96%), Champlain Investment Partners LLC (3.87%), Eagle Asset Management Inc. (3.31%), Royal Bank of Canada (1.96%) and Westwood Holdings Group Inc. (1.67%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Russell Investments Group Ltd., Oak Ridge Investments LLC, Mesirow Financial Investment Management Equity Management, Westfield Capital Management Co. LP, Fisher Asset Management LLC, Eagle Asset Management Inc. and JPMorgan Chase & Co.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, Jorge R Taborga, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.

Which major investors are buying Omnicell stock?

OMCL stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Penn Capital Management Co. Inc., Intrinsic Edge Capital Management LLC, Westwood Holdings Group Inc., New York State Common Retirement Fund, Fort Washington Investment Advisors Inc. OH, Global Alpha Capital Management Ltd. and Sio Capital Management LLC. View Insider Buying and Selling for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $45.85.

How big of a company is Omnicell?

Omnicell has a market capitalization of $1.78 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]

MarketBeat Community Rating for Omnicell (OMCL)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		286 (Vote Outperform)
Underperform Votes:		209 (Vote Underperform)
Total Votes:		495

MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Omnicell (NASDAQ:OMCL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Omnicell in the last 12 months. Their average twelve-month price target is $56.6667, suggesting that the stock has a possible upside of 23.59%. The high price target for OMCL is $67.00 and the low price target for OMCL is $44.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.71	2.86
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$56.6667	$56.6667	$56.1429	$54.8571
Price Target Upside:	23.59% upside	33.81% upside	24.07% upside	7.99% upside

Omnicell (NASDAQ:OMCL) Consensus Price Target History

Price Target History for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ:OMCL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$63.00	Medium
2/2/2018	Piper Jaffray Companies	Boost Price Target	Neutral ➝ Neutral	$38.00 ➝ $44.00	High
2/2/2018	Craig Hallum	Downgrade	Buy ➝ Hold		High
1/29/2018	Oppenheimer	Reiterated Rating	Buy	$55.00	Medium
9/5/2017	Benchmark	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $67.00	Medium
7/28/2017	Dougherty & Co	Boost Price Target	Buy	$45.00 ➝ $49.00	High
4/26/2017	CIBC	Boost Price Target	Outperform	$43.00 ➝ $53.00	Low
9/8/2016	Sidoti	Downgrade	Buy ➝ Neutral	$43.00	N/A
7/29/2016	FBR & Co	Boost Price Target	Outperform	$40.00 ➝ $41.00	N/A

(Data available from 5/27/2016 forward)

Omnicell (NASDAQ:OMCL) Earnings History and Estimates Chart

Earnings by Quarter for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ:OMCL) Earnings Estimates

Current Year EPS Consensus Estimate: $1.38 EPS
Next Year EPS Consensus Estimate: $1.69 EPS

Omnicell (NASDAQ OMCL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/25/2018		$0.39					N/A
4/26/2018	Q1 2018	$0.25	$0.29	$177.49 million	$182.60 million	View	N/A
2/1/2018	Q4 2017	$0.52	$0.54	$205.50 million	$198.26 million	View	Listen
10/26/2017	Q3 2017	$0.42	$0.42	$192.45 million	$186.78 million	View	N/A
7/27/2017	Q2 2017	$0.02	$0.02	$174.08 million	$180.90 million	View	N/A
5/4/2017	Q1 2017	($0.30)	$0.06	$152.63 million	$150.90 million	View	Listen
2/15/2017	Q4 2016	$0.41	$0.37	$179.28 million	$171.97 million	View	Listen
10/27/2016	Q316	$0.41	$0.40	$179.75 million	$179.40 million	View	Listen
7/28/2016	Q216	$0.32	$0.38	$170.89 million	$175.60 million	View	Listen
4/28/2016	Q116	$0.26	$0.35	$167.18 million	$171.00 million	View	Listen
2/4/2016	Q415	$0.39	$0.40	$126.89 million	$130.30 million	View	Listen
10/29/2015	Q315	$0.36	$0.36	$128.50 million	$125.20 million	View	Listen
7/30/2015	Q215	$0.32	$0.28	$121.35 million	$112.80 million	View	Listen
4/30/2015	Q115	$0.23	$0.29	$112.00 million	$16.20 million	View	N/A
2/3/2015	Q414	$0.33	$0.39	$114.65 million	$121.50 million	View	Listen
10/30/2014	Q314	$0.31	$0.30	$106.10 million	$112.50 million	View	Listen
7/31/2014	Q214	$0.29	$0.30	$103.23 million	$105.10 million	View	Listen
5/1/2014	Q114	$0.24	$0.26	$97.49 million	$101.80 million	View	Listen
2/4/2014	Q413	$0.28	$0.29	$101.13 million	$105.80 million	View	Listen
10/31/2013	Q313	$0.28	$0.31	$94.96 million	$94.03 million	View	N/A
8/1/2013	Q2 2013	$0.25	$0.27	$92.42 million	$93.70 million	View	N/A
5/2/2013	Q1 2013	$0.19	$0.21	$87.20 million	$87.11 million	View	N/A
1/31/2013	Q4 2012	$0.25	$0.25	$87.31 million	$90.16 million	View	N/A
10/25/2012		$0.22	$0.29			View	N/A
8/1/2012		$0.18	$0.20			View	N/A
5/2/2012		$0.13	$0.13			View	N/A
1/26/2012		$0.16	$0.19			View	N/A
10/27/2011		$0.16	$0.16			View	N/A
7/28/2011		$0.13	$0.15			View	N/A
5/2/2011		$0.10	$0.11			View	N/A
1/27/2011		$0.12	$0.11			View	N/A
10/27/2010	Q3 2010	$0.02	$0.02			View	N/A
7/22/2010	Q2 2010	$0.04	$0.06			View	N/A
4/26/2010	Q1 2010	$0.02	$0.03			View	N/A
1/28/2010	Q4 2009	$0.03	$0.02			View	N/A
10/22/2009	Q3 2009	$0.02	$0.03			View	N/A
7/23/2009	Q2 2009	$0.01	$0.03			View	N/A
4/30/2009	Q1 2009	($0.02)	($0.01)			View	N/A
1/29/2009	Q4 2008	$0.07	$0.10			View	N/A
10/23/2008	Q3 2008	$0.09	$0.09			View	N/A
7/21/2008	Q2 2008	$0.08	$0.09			View	N/A
4/21/2008	Q1 2008	$0.11	$0.11			View	N/A
1/31/2008	Q4 2007	$0.20	$0.21			View	N/A

(Earnings results data provided by Zacks Investment Research)

Omnicell (NASDAQ:OMCL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Omnicell (NASDAQ OMCL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.71%
Institutional Ownership Percentage: 98.00%

Insider Trading History for Omnicell (NASDAQ:OMCL)

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ OMCL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/17/2018	Gary S Petersmeyer	Director	Sell	1,650	$46.13	$76,114.50
5/15/2018	Robin Gene Seim	Insider	Sell	13,286	$46.48	$617,533.28	74,121
5/11/2018	Peter J Kuipers	Insider	Sell	3,456	$47.62	$164,574.72	56,970
4/16/2018	Dan S Johnston	EVP	Sell	11,284	$44.95	$507,215.80	46,430
4/12/2018	Peter J Kuipers	Insider	Sell	724	$46.00	$33,304.00	56,970
3/15/2018	Gary S Petersmeyer	Director	Sell	575	$44.43	$25,547.25
3/6/2018	Randall A Lipps	Chairman	Sell	8,186	$44.21	$361,903.06	224,206
12/18/2017	Peter J Kuipers	CFO	Sell	1,926	$51.69	$99,554.94	40,544
11/17/2017	Dan S Johnston	EVP	Sell	14,613	$47.81	$698,647.53	43,621
11/17/2017	Peter J Kuipers	VP	Sell	4,724	$47.74	$225,523.76	40,544
11/6/2017	Jorge R Taborga	VP	Sell	6,295	$48.69	$306,503.55	50,013
10/2/2017	Peter J Kuipers	VP	Sell	3,532	$50.96	$179,990.72	40,714
9/15/2017	Robin Gene Seim	EVP	Sell	9,780	$48.97	$478,926.60	55,896
9/5/2017	Gary S. Petersmeyer	Director	Sell	1,000	$51.73	$51,730.00
9/1/2017	Randall A. Lipps	Chairman	Sell	10,625	$52.00	$552,500.00
8/18/2017	Dan S Johnston	EVP	Sell	16,400	$48.86	$801,304.00	51,621
8/15/2017	Robin Gene Seim	EVP	Sell	15,109	$50.86	$768,443.74	58,144
8/9/2017	Peter J Kuipers	VP	Sell	18,054	$50.31	$908,296.74	44,236
8/8/2017	J Christopher Drew	VP	Sell	11,375	$51.16	$581,945.00	139,201
8/7/2017	Jorge R Taborga	VP	Sell	20,719	$50.98	$1,056,254.62	53,270
8/1/2017	Randall A Lipps	Chairman	Sell	40,000	$49.76	$1,990,400.00	196,551
7/28/2017	Randall A Lipps	Chairman	Sell	37,500	$46.00	$1,725,000.00	196,551
6/19/2017	Randall A Lipps	Chairman	Sell	31,527	$42.87	$1,351,562.49	196,551
6/5/2017	Randall A Lipps	Chairman	Sell	9,900	$43.00	$425,700.00	208,982
5/26/2017	James T Judson	Director	Sell	12,148	$41.50	$504,142.00	19,130
5/25/2017	Gary S Petersmeyer	Director	Sell	2,200	$41.41	$91,102.00	21,075
5/19/2017	Dan S Johnston	EVP	Sell	16,400	$40.67	$666,988.00	61,696
5/9/2017	J Christopher Drew	VP	Sell	10,625	$40.97	$435,306.25	152,057
4/25/2017	Randall A Lipps	Chairman	Sell	18,200	$41.00	$746,200.00	208,982
3/10/2017	Gary S Petersmeyer	Director	Sell	2,658	$37.45	$99,542.10	20,085
2/21/2017	Sara J White	Director	Sell	3,443	$38.06	$131,040.58	43,214
11/18/2016	Dan S Johnston	EVP	Sell	8,850	$33.65	$297,802.50	58,877
11/18/2016	Jorge R Taborga	VP	Sell	2,068	$33.66	$69,608.88	47,223
11/8/2016	J Christopher Drew	VP	Sell	20,000	$31.95	$639,000.00	139,844
9/12/2016	Gary S Petersmeyer	Director	Sell	2,000	$37.98	$75,960.00	17,987
9/8/2016	Gary S Petersmeyer	Director	Sell	2,400	$39.39	$94,536.00	17,987
9/6/2016	Gary S Petersmeyer	Director	Sell	2,000	$39.02	$78,040.00	19,987
9/2/2016	Gary S Petersmeyer	Director	Sell	3,000	$38.52	$115,560.00	19,987
8/19/2016	Dan S Johnston	EVP	Sell	8,850	$36.93	$326,830.50	64,877
8/19/2016	Jorge R Taborga	VP	Sell	1,778	$36.92	$65,643.76	49,073
8/11/2016	Randall A Lipps	Chairman	Sell	37,425	$37.37	$1,398,572.25	192,325
8/9/2016	J Christopher Drew	VP	Sell	15,000	$37.89	$568,350.00	139,844
8/9/2016	James T Judson	Director	Sell	6,250	$37.98	$237,375.00	15,300
8/4/2016	Gary S Petersmeyer	Director	Sell	8,750	$37.84	$331,100.00	19,987
7/29/2016	Jorge R Taborga	VP	Sell	10,023	$40.00	$400,920.00	49,073
7/6/2016	Robin Gene Seim	EVP	Sell	5,302	$34.75	$184,244.50	55,420
7/1/2016	Robin Gene Seim	EVP	Sell	3,645	$35.00	$127,575.00	55,420
6/6/2016	Jorge R Taborga	VP	Sell	25,979	$33.00	$857,307.00	50,734
5/24/2016	Gary S Petersmeyer	Director	Sell	6,250	$31.22	$195,125.00	15,557
5/20/2016	Dan S Johnston	EVP	Sell	8,850	$30.73	$271,960.50	73,105
5/20/2016	Jorge R Taborga	VP	Sell	1,933	$30.73	$59,401.09	52,667
5/10/2016	J Christopher Drew	VP	Sell	15,000	$31.63	$474,450.00	144,573
5/5/2016	Sara J White	Director	Sell	2,000	$31.76	$63,520.00	40,433
4/29/2016	Robin Gene Seim	EVP	Sell	6,407	$31.00	$198,617.00	59,619
4/26/2016	Jorge R Taborga	VP	Sell	23,827	$30.00	$714,810.00	52,667
4/26/2016	Robin Gene Seim	EVP	Sell	767	$30.00	$23,010.00	60,386
2/19/2016	Dan S Johnston	EVP	Sell	8,850	$27.41	$242,578.50	79,716
2/19/2016	Jorge R Taborga	VP	Sell	1,685	$27.42	$46,202.70	54,806
2/11/2016	Randall A. Lipps	CEO	Sell	40,000	$27.81	$1,112,400.00	204,705
2/9/2016	J Christopher Drew	VP	Sell	15,000	$27.57	$413,550.00	145,355
12/18/2015	Nhat H. Ngo	VP	Sell	4,069	$28.71	$116,820.99	23,431
11/17/2015	Dan S. Johnston	VP	Sell	2,500	$28.00	$70,000.00	66,393
11/10/2015	J Christopher Drew	VP	Sell	25,000	$26.79	$669,750.00	137,180
11/9/2015	Dan S. Johnston	VP	Sell	2,700	$27.29	$73,683.00	66,393
10/13/2015	Gary S. Petersmeyer	Director	Sell	670	$31.66	$21,212.20	15,557
8/13/2015	Robin Gene Seim	CFO	Sell	23,946	$35.63	$853,195.98
7/1/2015	Robin Gene Seim	CFO	Sell	19,582	$37.84	$740,982.88
6/17/2015	Nhat H Ngo	VP	Sell	4,067	$38.78	$157,718.26
6/2/2015	James T Judson	Director	Sell	8,032	$36.83	$295,818.56
6/2/2015	Nhat H Ngo	VP	Sell	6,375	$36.80	$234,600.00
5/26/2015	Sara J White	Director	Sell	4,000	$36.25	$145,000.00
5/7/2015	Dan S Johnston	VP	Sell	7,715	$34.25	$264,238.75
2/12/2015	J Christopher Drew	VP	Sell	25,000	$34.62	$865,500.00
2/6/2015	Dan S Johnston	VP	Sell	6,552	$33.29	$218,116.08
2/2/2015	James T Judson	Director	Sell	5,000	$31.61	$158,050.00
1/13/2015	Gary S Petersmeyer	Director	Sell	670	$31.31	$20,977.70
1/2/2015	James T Judson	Director	Sell	5,000	$32.36	$161,800.00
1/2/2015	Robin Gene Seim	CFO	Sell	1,948	$32.36	$63,037.28
12/17/2014	Marga Ortigas-Wedekind	VP	Sell	4,080	$32.20	$131,376.00
12/15/2014	Gary S Petersmeyer	Director	Sell	670	$33.25	$22,277.50
12/8/2014	Nhat H Ngo	VP	Sell	1,754	$32.89	$57,689.06
12/1/2014	James T Judson	Director	Sell	5,000	$31.94	$159,700.00
11/12/2014	Randy D Lindholm	Director	Sell	5,000	$31.72	$158,600.00
11/11/2014	J Christopher Drew	VP	Sell	37,500	$31.86	$1,194,750.00
11/7/2014	Dan S Johnston	VP	Sell	27,625	$31.74	$876,817.50
11/3/2014	James T Judson	Director	Sell	5,000	$32.27	$161,350.00
10/3/2014	Nhat H Ngo	VP	Sell	2,275	$28.00	$63,700.00
10/1/2014	James T Judson	Director	Sell	5,000	$27.02	$135,100.00
9/15/2014	Jorge R Taborga	VP	Sell	944	$26.37	$24,893.28
9/15/2014	Robin Gene Seim	CFO	Sell	9,347	$26.32	$246,013.04
9/2/2014	James T Judson	Director	Sell	5,000	$28.18	$140,900.00
9/2/2014	Robin Gene Seim	CFO	Sell	27,500	$28.19	$775,225.00
8/26/2014	Dan S Johnston	VP	Sell	6,250	$28.00	$175,000.00
8/26/2014	James T Judson	Director	Sell	9,913	$27.91	$276,671.83
7/9/2014	Robin Gene Seim	CFO	Sell	2,442	$28.21	$68,888.82
7/1/2014	James T Judson	Director	Sell	5,000	$29.28	$146,400.00
6/26/2014	Marga Ortigas-Wedekind	VP	Sell	2,961	$28.17	$83,411.37
6/25/2014	Nhat H Ngo	VP	Sell	2,274	$28.00	$63,672.00
6/17/2014	Nhat H Ngo	VP	Sell	1,420	$27.70	$39,334.00
6/10/2014	Nhat H Ngo	VP	Sell	1,964	$26.38	$51,810.32
6/2/2014	Gary S Petersmeyer	Director	Sell	5,000	$26.45	$132,250.00
5/21/2014	Gary Petersmeyer	Director	Sell	2,000	$26.51	$53,020.00	17,088
5/13/2014	J Christopher Drew	VP	Sell	37,500	$26.08	$978,000.00	151,448
5/7/2014	Dan Johnston	VP	Sell	4,000	$25.25	$101,000.00	75,558
5/1/2014	James Judson	Director	Sell	5,000	$26.24	$131,200.00	17,945
4/8/2014	Nhat Ngo	VP	Sell	1,002	$27.40	$27,454.80	52,896
3/18/2014	Marga Ortigas-Wedekind	VP	Sell	5,880	$30.00	$176,400.00	53,445
3/18/2014	Randall Lipps	CEO	Sell	124,910	$29.89	$3,733,559.90	220,997
12/18/2013	Nhat Ngo	VP	Sell	1,462	$24.43	$35,716.66	45,585
12/18/2013	Randall Lipps	CEO	Sell	64,739	$24.30	$1,573,157.70	186,048
12/3/2013	Dan Johnston	VP	Sell	73,419	$23.24	$1,706,257.56	74,885
11/11/2013	Randy Lindholm	Director	Sell	3,587	$23.00	$82,501.00	26,917
11/7/2013	Dan Johnston	VP	Sell	8,000	$22.99	$183,920.00	74,885
10/23/2013	Robin Gene Seim	CFO	Sell	7,664	$24.50	$187,768.00
10/21/2013	Robin Gene Seim	CFO	Sell	9,349	$23.76	$222,132.24
10/1/2013	James T Judson	Director	Sell	5,000	$23.66	$118,300.00
9/24/2013	Randall Lipps	CEO	Sell	68,204	$25.00	$1,705,100.00	202,362
9/23/2013	Marga Ortigas-Wedekind	VP	Sell	4,000	$25.00	$100,000.00	80,903
9/23/2013	Randall Lipps	CEO	Sell	5,083	$25.00	$127,075.00	202,362
9/20/2013	Robin Gene Seim	CFO	Sell	27,500	$24.35	$669,625.00	69,700
9/18/2013	Randall Lipps	CEO	Sell	64,453	$23.67	$1,525,602.51	202,362
9/4/2013	Nhat H Ngo	VP	Sell	7,362	$24.00	$176,688.00
9/3/2013	James Judson	Director	Sell	5,000	$22.77	$113,850.00	17,945
8/20/2013	James Judson	Director	Sell	11,724	$22.74	$266,603.76	17,945
8/13/2013	J Christopher Drew	VP	Sell	20,000	$22.83	$456,600.00	131,221
8/12/2013	Donald Wegmiller	Director	Sell	34,976	$22.87	$799,901.12	8,002
8/7/2013	Dan Johnston	VP	Sell	8,000	$22.92	$183,360.00	74,885
8/6/2013	Randall Lipps	CEO	Sell	5,321	$23.00	$122,383.00	211,905
8/2/2013	Randall A Lipps	CEO	Sell	25,000	$22.50	$562,500.00
8/1/2013	James Judson	Director	Sell	5,000	$21.00	$105,000.00	29,669
7/19/2013	Nhat H Ngo	VP	Sell	41,875	$21.00	$879,375.00
7/19/2013	Randall A Lipps	CEO	Sell	5,080	$21.00	$106,680.00
7/1/2013	James T Judson	Director	Sell	5,000	$20.46	$102,300.00
7/1/2013	Robin Gene Seim	CFO	Sell	13,032	$20.42	$266,113.44
6/28/2013	Marga Ortigas-Wedekind	VP	Sell	4,545	$20.00	$90,900.00
6/28/2013	Randall A Lipps	CEO	Sell	25,000	$20.00	$500,000.00
6/21/2013	Nhat H Ngo	VP	Sell	3,459	$19.01	$65,755.59
6/18/2013	Randall A Lipps	CEO	Sell	66,378	$19.10	$1,267,819.80
6/10/2013	Randy D Lindholm	Director	Sell	23,901	$19.14	$457,465.14
6/4/2013	Robin Gene Seim	CFO	Sell	25,000	$18.72	$468,000.00
5/22/2013	Gary S Petersmeyer	Director	Sell	2,750	$18.10	$49,775.00
5/16/2013	J Christopher Drew	VP	Sell	26,000	$18.69	$485,940.00
5/14/2013	J Christopher Drew	VP	Sell	26,000	$18.45	$479,700.00
5/10/2013	Sara J White	Director	Sell	7,200	$18.50	$133,200.00
5/7/2013	Dan S Johnston	VP	Sell	8,000	$18.44	$147,520.00
12/3/2012	Gary S Petersmeyer	Director	Sell	1,359	$15.17	$20,616.03

(Data available from 1/1/2013 forward)

Omnicell (NASDAQ OMCL) News Headlines

Source:

Date	Headline
	Comparing Omnicell (OMCL) and Super Micro Computer (SMCI) www.americanbankingnews.com - May 25 at 10:06 AM
	VitalConnect Announces Joe Lynch as Chief Marketing Officer finance.yahoo.com - May 24 at 4:34 PM
	Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $188.53 Million www.americanbankingnews.com - May 24 at 4:50 AM
	Omnicell Technologies (OMCL) Expected to Announce Earnings of $0.40 Per Share www.americanbankingnews.com - May 22 at 9:10 AM
	Insider Selling: Omnicell Technologies (OMCL) Director Sells 1,650 Shares of Stock www.americanbankingnews.com - May 17 at 8:33 PM
	Omnicell Technologies (OMCL) Insider Sells $617,533.28 in Stock www.americanbankingnews.com - May 16 at 1:24 PM
	Contrasting Omnicell Technologies (OMCL) and Cray (CRAY) www.americanbankingnews.com - May 15 at 10:46 AM
	Insider Selling: Omnicell Technologies (OMCL) Insider Sells 3,456 Shares of Stock www.americanbankingnews.com - May 14 at 1:21 PM
	Contrasting Omnicell Technologies (OMCL) and Super Micro Computer (SMCI) www.americanbankingnews.com - May 13 at 9:09 PM
	Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency ... www.prnewswire.com - May 12 at 10:03 AM
	Omnicell Technologies (OMCL) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - May 10 at 4:37 PM
	Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety in Central Pharmacy Operations finance.yahoo.com - May 10 at 9:37 AM
	Omnicell Technologies (OMCL) versus Capcom (CCOEY) Head-To-Head Comparison www.americanbankingnews.com - May 9 at 3:13 AM
	Omnicell Technologies (OMCL) Expected to Announce Quarterly Sales of $188.50 Million www.americanbankingnews.com - May 6 at 2:02 AM
	Fitbit (FIT) vs. Omnicell Technologies (OMCL) Critical Contrast www.americanbankingnews.com - May 5 at 10:13 AM
	Omnicell Technologies (OMCL) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - May 5 at 6:37 AM
	$0.40 EPS Expected for Omnicell Technologies (OMCL) This Quarter www.americanbankingnews.com - May 4 at 11:17 PM
	Reviewing Teradata (TDC) and Omnicell Technologies (OMCL) www.americanbankingnews.com - May 2 at 10:56 AM
	Edited Transcript of OMCL earnings conference call or presentation 26-Apr-18 8:30pm GMT finance.yahoo.com - April 28 at 9:48 AM
	Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1 finance.yahoo.com - April 27 at 4:30 PM
	Omnicell Technologies (OMCL) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS www.americanbankingnews.com - April 27 at 4:12 PM
	Omnicell's (OMCL) CEO Randall Lipps on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 27 at 9:56 AM
	Omnicell: 1Q Earnings Snapshot finance.yahoo.com - April 27 at 9:56 AM
	Omnicell Technologies (OMCL) Updates Q2 Earnings Guidance www.americanbankingnews.com - April 26 at 7:28 PM
	Omnicell Technologies (OMCL) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 26 at 7:28 PM
	Omnicell Announces First Quarter 2018 Results finance.yahoo.com - April 26 at 4:30 PM
	Omnicell Technologies (OMCL) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - April 25 at 2:20 AM
	Analyzing Apple (AAPL) & Omnicell Technologies (OMCL) www.americanbankingnews.com - April 23 at 9:06 PM
	Omnicell Technologies (OMCL) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 20 at 11:17 AM
	Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018 finance.yahoo.com - April 19 at 4:42 PM
	Omnicell Technologies (OMCL) Expected to Post Quarterly Sales of $177.37 Million www.americanbankingnews.com - April 19 at 2:12 AM
	Omnicell Technologies (OMCL) Expected to Post Earnings of $0.27 Per Share www.americanbankingnews.com - April 17 at 9:12 PM
	Omnicell Technologies (OMCL) EVP Dan S. Johnston Sells 11,284 Shares www.americanbankingnews.com - April 16 at 7:14 PM
	Analyzing Omnicell Technologies (OMCL) and Teradata (TDC) www.americanbankingnews.com - April 15 at 9:09 PM
	Omnicell Technologies (OMCL) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - April 15 at 11:29 AM
	Omnicell Technologies (OMCL) Insider Sells $33,304.00 in Stock www.americanbankingnews.com - April 12 at 7:35 PM
	Omnicell Technologies (OMCL) versus Dell Technologies (DVMT) Financial Contrast www.americanbankingnews.com - April 12 at 1:29 AM
	Comparing Omnicell Technologies (OMCL) & NICE Systems (NICE) www.americanbankingnews.com - April 11 at 8:45 AM
	Omnicell's Medication Management Automation Portfolio to Be Featured at the American Organization of Nurse Executives 2018 Conference finance.yahoo.com - April 10 at 9:49 AM
	Head-To-Head Review: Omnicell Technologies (OMCL) & Capcom (CCOEY) www.americanbankingnews.com - April 10 at 1:31 AM
	Omnicell Appoints Scott Seidelmann as Chief Commercial Officer finance.yahoo.com - April 9 at 9:38 AM
	Omnicell Technologies (OMCL) Upgraded by BidaskClub to "Hold" www.americanbankingnews.com - April 7 at 9:29 AM
	Craig Hallum Reaffirms "Buy" Rating for Omnicell Technologies (OMCL) www.americanbankingnews.com - April 4 at 1:21 PM
	Omnicell Technologies (OMCL) Earns Buy Rating from Cantor Fitzgerald www.americanbankingnews.com - April 3 at 5:16 PM
	Omnicell Technologies (OMCL) Expected to Announce Quarterly Sales of $177.37 Million www.americanbankingnews.com - April 2 at 2:08 AM
	$0.27 Earnings Per Share Expected for Omnicell Technologies (OMCL) This Quarter www.americanbankingnews.com - March 31 at 9:08 PM
	Reviewing Omnicell Technologies (OMCL) & Cancer Genetics (CGIX) www.americanbankingnews.com - March 27 at 3:20 PM
	Mercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety finance.yahoo.com - March 27 at 9:49 AM
	Omnicell (OMCL) Upgraded at BidaskClub www.americanbankingnews.com - March 24 at 6:46 PM
	Head to Head Contrast: Omnicell (OMCL) and The Ensign Group (ENSG) www.americanbankingnews.com - March 23 at 1:32 AM

Omnicell (NASDAQ:OMCL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Omnicell (NASDAQ:OMCL) Income Statement, Balance Sheet and Cash Flow Statement

Omnicell (NASDAQ OMCL) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff